Form 4: Akebia Therapeutics Director Exercises Stock Options
SEC Form 4 Filing
Director Ronald Frieson exercised stock options to acquire 20,100 shares of Akebia Therapeutics common stock at $0.45 per share on January 17, 2025.
Summary
- On January 17, 2025, Ronald Frieson, a director of Akebia Therapeutics, Inc., exercised stock options.
- This transaction involved the acquisition of 20,100 shares of common stock at a price of $0.45 per share.
- Following the transaction, Frieson directly owns 93,800 shares of Akebia Therapeutics common stock.
- The stock options were originally granted on June 8, 2023, and are exercisable until June 8, 2032.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a stock option exercise, which is neutral in sentiment.
Industry Context
This is a routine disclosure related to insider transactions and provides insight into the actions of company directors, which can be of interest to investors.
Key Dates
| Date | Description |
|---|---|
| 06/08/2023 | Date the stock options were granted. |
| 01/17/2025 | Date of the stock option exercise. |
| 01/22/2025 | Date of the signature on the Form 4. |
| 06/08/2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.